The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
Open accessAbstract
BRAF, a cellular oncogene and effector of RAS-mediated signaling, is activated by mutation in ∼60% of melanomas. Most of these mutations consist of a V600E substitution resulting in constitutive kinase activation. Mutant BRAF thus represents an important therapeutic target in melanoma. In an effort to produce a pre-clinical model of mutant BRAF function in melanoma, we have generated a mouse expressing BRAF V600E targeted to melanocytes. We show that in these transgenic mice, widespread benign melanocytic hyperplasia with histological features of nevi occurs, with biochemical evidence of senescence. Melanocytic hyperplasia progresses to overt melanoma with an incidence dependent on BRAF expression levels. Melanomas show CDKN2A loss, and genetic disruption of the CDKN2A locus greatly enhances melanoma formation, consistent with collaboration between BRAF activation and CDKN2A loss suggested from studies of human melanoma. The development of melanoma also involves activation of the Mapk and Akt signaling pathways and loss of senescence, findings that faithfully recapitulate those seen in human melanomas. This murine model of mutant BRAF-induced melanoma formation thus provides an important tool for identifying further genetic alterations that cooperates with BRAF and that may be useful in enhancing susceptibility to BRAF-targeted therapeutics in melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“The loss of the p14ARF product of the Cdkna2a locus (Pomerantz et al., 1998; Zhang et al., 1998; Christophorou et al., 2006) renders p53 mutation superfluous, as supported by cell line data, which show Oncogene that most p53 mutations occur in melanoma when the Cdkna2a locus is normal (Haluska et…”
A negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382
Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166
Cited by
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Senescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Mitra, D., Luo, X., Morgan, A., Wang, J., Hoang, M. P., Lo, J., Guerrero, C. R., Lennerz, J. K., Mihm, M. C., Wargo, J. A., et al. (2012) · Nature · doi:10.1038/nature11624 · Cited by 497
Focus on the Contribution of Oxidative Stress in Skin Aging
Papaccio, F., D′Arino, A., Caputo, S., & Bellei, B. (2022) · Antioxidants · doi:10.3390/antiox11061121 · Cited by 396
Cellular senescence in osteoarthritis pathology
McCulloch, K., Litherland, G. J., & Rai, T. S. (2017) · Aging Cell · doi:10.1111/acel.12562 · Cited by 367
“Senescence is known to evoke tumor suppression, and it is widely accepted that senescence functions as a protective mechanism against cancer due to its ability to induce the proliferation arrest of damaged cells (Michaloglou et al., 2005; Dhomen et al., 2009; Goel et al., 2009).”
BackgroundMDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
Raf kinases in cancer–roles and therapeutic opportunities
Maurer, G., Tarkowski, B., & Baccarini, M. (2011) · Oncogene · doi:10.1038/onc.2011.160 · Cited by 292
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedThe Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Vredeveld, L. C. W., Possik, P. A., Smit, M. A., Meissl, K., Michaloglou, C., Horlings, H. M., Ajouaou, A., Kortman, P. C., Dankort, D., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.187252.112 · Cited by 262
Oncogene-induced senescence: the bright and dark side of the response
Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257
Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53
Viros, A., Sanchez-Laorden, B., Pedersen, M., Furney, S. J., Rae, J., Hogan, K., Ejiama, S., Girotti, M. R., Cook, M., Dhomen, N., et al. (2014) · Nature · doi:10.1038/nature13298 · Cited by 249
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation
Damsky, W., Micevic, G., Meeth, K., Muthusamy, V., Curley, D. P., Santhanakrishnan, M., Erdelyi, I., Platt, J. T., Huang, L., Theodosakis, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.014 · Cited by 142
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
The roles of microphthalmia-associated transcription factor and pigmentation in melanoma
Hsiao, J. J., & Fisher, D. E. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.019 · Cited by 148
Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2405 · Cited by 115
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
Nogueira, C., Kim, K.-H., Sung, H., Paraiso, K. H. T., Dannenberg, J.-H., Bosenberg, M., Chin, L., & Kim, M. (2010) · Oncogene · doi:10.1038/onc.2010.349 · Cited by 108
“, 2009) with rare progression to melanoma (Dhomen et al., 2009; Goel et al., 2009).”
Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1339 · Cited by 105
Cellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
Suppression of p16 alleviates the senescence-associated secretory phenotype
(2021) · doi:10.18632/aging.202640 · Cited by 84
Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC
Luo, C., Sheng, J., Hu, M. G., Haluska, F. G., Cui, R., Xu, Z., Tsichlis, P. N., Hu, G.-F., & Hinds, P. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4454 · Cited by 31
Self-citation
Metadata
- Authors
- Goel, V. K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., Westmoreland, S., Haluska, F. S., Hinds, P. W., & Haluska, F. G.
- Venue
- Oncogene
- Published
- 2009-04-27
- Volume
- 28
- Issue
- 23
- Pages
- 2289-2298
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1991053141
- Cited by
- 165
- References
- 11
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.